Blood Transfusion Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Spine (Phila Pa 1976). 2009 Nov 1;34(23):2479-85. doi: 10.1097/BRS.0b013e3181bd163f.
Prospective, open-label, randomized, parallel-group study at 80 centers.
To demonstrate there is no clinically important additional risk for deep vein thrombosis with perioperative use of epoetin alfa versus standard of care in spine surgery without prophylactic anticoagulation.
Trials of epoetin alfa in orthopedic surgery that demonstrated no additional risk of thrombovascular events included perioperative pharmacologic anticoagulation.
Subjects received epoetin alfa 600 U/kg subcutaneously once weekly starting 3 weeks before spinal surgery plus standard of care for blood conservation, or standard of care alone. Perioperative anticoagulation therapy was not permitted; mechanical deep vein thrombosis prophylaxis was allowed. Doppler imaging for deep vein thrombosis was done on postoperative day 4 (or day of discharge), or for suspected deep vein thrombosis. Deep vein thrombosis was diagnosed by Doppler result or adverse event report. The criterion for no additional risk of deep vein thrombosis was a 1-sided 97.5% upper confidence limit < or =4% between groups.
Of the 680 subjects analyzed (340 in each treatment group), 16 (4.7%) in the epoetin alfa group and 7 (2.1%) in the standard of care group had a diagnosis of deep vein thrombosis either by Doppler or by adverse event report with normal Doppler. The between-group difference was 2.6% (97.5% upper confidence limit, 5.4%). Deep vein thrombosis confirmed by Doppler (4.1% vs. 2.1%), other clinically relevant thrombovascular events (1.5% vs. 0.9%), and all adverse events combined (76.5% vs. 73.2%) occurred with similar frequency in the 2 treatment groups.
This study documented a higher incidence of deep vein thrombosis and similar rates of other clinically relevant thrombovascular events with epoetin alfa versus standard of care for blood conservation in subjects who did not receive prophylactic anticoagulation before spinal surgery. Antithrombotic prophylaxis should be considered when erythropoietin is used in the surgical setting.
80 个中心进行的前瞻性、开放标签、随机、平行组研究。
证明在没有预防性抗凝的情况下,围手术期使用促红细胞生成素阿尔法与标准护理相比,不会增加脊柱手术深静脉血栓形成的临床风险。
在骨科手术中进行的促红细胞生成素阿尔法试验表明,没有血栓血管事件的额外风险,包括围手术期药物抗凝。
受试者接受每周一次皮下注射 600U/kg 的促红细胞生成素阿尔法,从脊柱手术前 3 周开始,加标准护理的血液保护,或单独接受标准护理。不允许使用围手术期抗凝治疗;允许使用机械性深静脉血栓形成预防。术后第 4 天(或出院当天)或疑似深静脉血栓形成时进行深静脉血栓形成多普勒成像。深静脉血栓形成通过多普勒结果或不良事件报告进行诊断。深静脉血栓形成无额外风险的标准是组间单侧 97.5%置信上限<或=4%。
在分析的 680 名受试者中(每组 340 名),促红细胞生成素阿尔法组有 16 名(4.7%)和标准护理组有 7 名(2.1%)通过多普勒或正常多普勒的不良事件报告诊断为深静脉血栓形成。组间差异为 2.6%(单侧 97.5%置信上限,5.4%)。通过多普勒证实的深静脉血栓形成(4.1%对 2.1%)、其他临床相关血栓血管事件(1.5%对 0.9%)和所有不良事件的综合发生率在两组中相似。
这项研究证明,在未接受脊柱手术前预防性抗凝的情况下,与标准护理血液保护相比,促红细胞生成素阿尔法的深静脉血栓形成发生率更高,其他临床相关血栓血管事件的发生率相似。在手术环境中使用红细胞生成素时应考虑抗血栓形成预防。